WO1993022286A1 - Novel tetracyclic compound - Google Patents
Novel tetracyclic compound Download PDFInfo
- Publication number
- WO1993022286A1 WO1993022286A1 PCT/JP1993/000527 JP9300527W WO9322286A1 WO 1993022286 A1 WO1993022286 A1 WO 1993022286A1 JP 9300527 W JP9300527 W JP 9300527W WO 9322286 A1 WO9322286 A1 WO 9322286A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mmol
- added
- dissolved
- compound
- water
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
Definitions
- the present invention relates to a method for forming 5 shelves for use as shelves.
- R 1 is C 0 2 H, etc., R 2 and R 3 are completely H, F, etc., R 4 and R 5
- X 1 and X 2 are the same or different, and are hydrogen or lower alkyl II ⁇ , and II is 144 ⁇ ) or its ⁇ F. .
- the lower alkyl is a dragon or a suffix of 1-6, such as', methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl. , Neopentyl and hexino 1.
- the salt of (I) is Ammonium ⁇ , organic amines f3 ⁇ 4D ⁇ , amino acids ffiSt ⁇ T.
- Examples of the i-agent include polyphosphoric acid, methanesulfonic acid, and the like.
- ⁇ (II) can be obtained according to the following J®S process.
- the compound (II-a) in which n is 2 or 3 in Harajuku (II) can be obtained according to the following sisi.
- ⁇ (V) is the power to follow the next si ig n
- n is the same as the knitting, ⁇ ', Bu is butyl, Z is ⁇ , iodine or trifluorosulfonyl
- the chemical formula ⁇ / (I I I) can be synthesized by the method of CJ. Org. Chem (Journal of Organic Chemistry), 70 (1962)] or a method analogous thereto.
- the chemical formula J (XIV) can be determined by the method of CAngew.ChenLlnt.E Engl. (Angevante 'Chemie International' Edition-Indlinglish),, 508 (1986)) or a similar method.
- X 1 and Z or X 2 can be replaced with alkyl 2 to 4 under formula KiJ3 ⁇ 4.
- Examples include n-butyllithium, potassium tert-butoxide, sodium hydride, sodium arsenate, keyium lium, and triethylamine.
- step 11 1 to 5 equivalents of Grignano ⁇ may be reacted with compound (III) in ether, tetrahydrofuran, dioxane ⁇ , usually at 130 to 100 ° C for 5 to 12 Bf ⁇ , and Two equivalents of triethylsilane are prepared by letting S ⁇ S ⁇ 70 ° C for 5 minutes ⁇ 6 ⁇ RiS by Trihnoreolo Satchu ⁇ ! (XV) can be gained.
- ⁇ (XVI) and ⁇ (VI) can be obtained by the same method as in ⁇ IS about 4.
- Compound (XVI I) is converted to dichloromethane, dichloroethane ⁇ ⁇ SIS under an equivalent amount of aluminum trichloride Lewis ⁇ ⁇ in a f ⁇ dish, usually at 0 ° C ⁇ ⁇ by subjecting to 1 ⁇ 12 ⁇ ⁇ 3 ⁇ 40®. XV III) to gain power.
- N is 2 or 3 in ⁇ ⁇ (I I I) ⁇ ! (III-a) and methyl iodide, 'Yoide etchizo ⁇ ) alkyl halide in tetrahydrofuran, dioxas dimethylformamide, dimethylsulfoxide, usually at 0 to 120 ° C for 5 minutes to 12 ⁇ ⁇ Power to gain (XX)
- Examples include sodium hydride, potassium tert-butoxide, cinnamate, potassium potassium, and the like. If necessary, tetrabutylammonium bromide ⁇ quaternary ammonium / ride salt or the like, or 18-crown-16 crown atheno ⁇ phase yeast fiber may be used.
- the compound ⁇ / (XXI I) can be obtained from dani ⁇ / (XXI) by the same method as ⁇ ⁇ 3 ⁇ 43.
- salt of chemical compound (I) Dissolve or suspend in Nada It is made cloudy, and acid or w ⁇ is added to form a salt, which is good.
- the compound ⁇ / (I) and its ⁇ fp-capable salt may be 0 with water or each other, and these 3 are also included in the present invention.
- the yeast was suspended at 200 Orpm for 5 ⁇ 1: 1:, suspended in 1 ml of hanks ' ⁇ , separated and re-dissolved, and then 1 ml of hanks' suspended.
- This 501 was added to a 0.25% agarose 'hanks, preheated to 50 ° C, 400 ⁇ ⁇ ⁇ together with 50 u ⁇ of hidge erythrocytes, spread on a slide glass, placed on a plaque atssay plate, and subjected to a 40-fold increase in phosphorus.
- guinea pig complement (sedalene f ⁇ ) at 37, 1-2, the haemolysis that appeared appeared 3 ⁇ 4 ⁇ 3 ⁇ 4 (directed PFCI ⁇ .
- the number of PFCs in the control D-number of PFCs in the presence of the drug was calculated as follows:
- Randai ⁇ (Kake ⁇ 3 ⁇ 43) observed the 5% gum arabic sickle and treated the adjuvant with Day 0, once a day, Day 0-4, Day 7-11, Day 14-16 Oral administration.
- the pirate of the present invention can be used as a pirates by mixing a large amount of (I) or its mi-capable salt with a carrier supported by mhF.
- the body can take a wide variety of forms, depending on the preferred form of administration. It is highly desirable that these snakes be in single digger form suitable for oral or Nada administration.
- any useful carrier can be used.
- oral fluids such as syrup and syrup U may be water, sucrose, sorbitol, fructose, etc .; ⁇ ⁇ glycoglycones such as polyethylene glycol, propylene glycol:!, Sesame oil, olive oil, ⁇ , etc. It can be protected by a variety of flavors such as anti-block, alkyl p-hydroxybenzoate, etc., berry flavor, and mint.
- Powders, Ml force pseno and wok are used for powders such as lactose, glucose, sucrose, mannitol, starch, starch and sodium alginate, magnesium stearate, talc, etc.
- G ⁇ can be obtained using agents such as polyvinyl alcohol, hydroxypropylcellulose, and gelatin; Fines and capsules are the most useful monofemoral preparations because they are the dosage form. Watch the weaves and capsules When doing so, a solid ⁇ a body is used. --You can also use a distilling, glucose sickle or (ii ⁇ j and glucose carrier).
- Compound (I) or its salt can be administered orally or orally by mouth and its dose may vary depending on the dosage form, patient, health, and m. However, it is effective to administer 1 to 5 Omg kg per day in 3 to 4 divided doses.
- Figure 1 shows adjuvant-treated rats 3 ⁇ 43 ⁇ 493 ⁇ 4 £ ⁇ W ⁇ ⁇ ⁇ .
- 110 is the controller -Low (Dose; 3mgAg)
- Figure 2 shows the adjuvant non-healing rat ⁇
- 101 is Controso--amibm m.; S- ⁇ -1),
- ⁇ ⁇ ⁇ 3 ⁇ 45.9 g was dissolved in 20 ml of dioxane, and 4ii3 ⁇ 47j «sodium salt was added. The wake was added to the EE residue, 50 ml of water was added, and the mixture was washed with ether. After adding 20 ml of 6-experiment fiber to the mixture, the mixture was extracted with awake ethyl. After ⁇ 03 ⁇ 4 ⁇ ], the ⁇ magnesium was dried. Nada was distilled off to give 5.2 g (97% yield) of a mixture of 4- (2-furenolelophenyl) benziso! And 2- (2-fluorophenyl) benz Af ⁇ .
- Example 2 35 g of the compound obtained in Example 2 was dissolved in 1 ml of propionic acid and 4 ml of profession, and 1.91 g of chromic acid dissolved in 7.2 ml of gurin water (7: 1) ( (19.1 millimoles) at 0 ° C. Sodium and ethyl were added to the liquid for extraction. Anhydrous magnesium.
- the nada was refined in a furnace using E ⁇ silica gel column chromatography I distilling; 4% ethyl hexane] to obtain 0 g (yield 70%) of self-reliant ⁇ JL.
- Example 7 4.5 g of the compound obtained in Example 7 was dissolved in 6 ml of propionic acid and 23 ml of occupational solution, and 0.93 g (59.3 mmol) of chromium dissolved in 24 ml of occupational water (7: 1) was added at o ° c. Originally, ⁇ said at 12 ⁇ f. ⁇ It solution was extracted by adding 3 ⁇ 43 ⁇ 4 sodium ⁇ Tkit ⁇ and ⁇ ethyl. ⁇ 7] 0 ⁇ and then anhydrous »Magnesium! I did. The furnace was purified with silica gel column chromatography; Hexane Ichigen (9: 1)] to obtain 0.75 g of a self-produced product (58% yield from the chemical compound / f).
- Example 9 3.8 g (13.3 mmol) of the compound obtained in Example 9 was dissolved in 20 ml of trifluoroacetic acid, 5.22 ml (32.5 mmol) of triethylsilane was added, and the mixture was stirred at 70 ° C. for 3 hours.
- the porcelain was extracted by adding black-and-white form and water. ⁇ m waterless magnesium.
- the nada was crystallized from methylene chloride and hexane to obtain 2.7 g (yield 75%).
- Example 12 The compound ⁇ II 2.Og obtained in Example 12 was dissolved in 3 ml of propionic acid and 12 ml of hard solution, and chromium ⁇ 2.5 g (249 mmol) dissolved in 2 ml of Satsumizu (7: 1) I was dissolved.
- the str solution was subjected to cerium filtration, washed with water and water, and extracted to obtain magnesium. After leaving the office, the product was purified by silica gel column chromatography using a silica gel (hexane: 9: 1) to obtain 0.84 g (40%) of the polymer.
- the Nada was distilled off, the ⁇ was dissolved in 3 Oml of ethanol, 150 mg of palladium / working powder was added, and under a hydrogen atmosphere, ⁇ 4 was used in a hydrogen atmosphere. After filtration through Celite No. 1, the residue was purified by silica gel column chromatography I Nadadome, Idanada; hexane] to obtain 1.80 g (60%) of the enemied compound.
- Example 23 2.3 g of the compound obtained in Example 23 was dissolved in 2.7 ml of propionic acid and 10 ml of leak, and 2.71 g (2.71 mmol) of chromic acid dissolved in 10 ml of sleep water (7: 1) ) was added at 0 ° C, and 3 stormed. Sodium and sodium chill were added to the Sit solution and extracted. «Washed: ⁇ i7jO? The nada was purified by E-drain and sie gel gel ram chromatography [ ⁇ Denada; Hexane-Ethyl ethyl (10: 1)] to obtain 15 g (70% yield) of Nishido.
- Example 28 8- (2-Funoleolophenyl) 1-2-methyl-1H—2,3,4,5-tetrahydrobenzocycloheptene (I-Dana of course bb)-'The compound obtained in Example 27 ⁇ / aa 2. 98 g (11.1 mmol) was dissolved in 25 ml of trifluoroacetic acid, and 4.28 ml (26.6 mmol) of triethylsilane was added.
- Example 30 % 2.22 g (7.87 mmol) of the compound obtained in Example 30 was dissolved in 25 ml of trifluoroacetic acid, and 3.03 ml (18.9 mmol) of triethylsilane was added thereto. The porcelain form and water were added to ⁇ ⁇ ⁇ , and was added, and anhydrous magnesium was added. E was distilled off and purified by silica gel column chromatography. Hexane], and self-sufficiency was obtained.
- the capsu was formed as follows.
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5519122A JP2928385B2 (ja) | 1992-04-24 | 1993-04-23 | 新規四環系化合物 |
DE69319859T DE69319859T2 (de) | 1992-04-24 | 1993-04-23 | Neue tetracyclische verbindungen |
EP93909411A EP0601191B1 (en) | 1992-04-24 | 1993-04-23 | Novel tetracyclic compound |
DK93909411T DK0601191T3 (da) | 1992-04-24 | 1993-04-23 | Hidtil ukendt tetracyklisk forbindelse |
US08/170,192 US5371225A (en) | 1992-04-24 | 1993-04-23 | Tetracyclic compounds |
CA002111955A CA2111955C (en) | 1992-04-24 | 1993-04-23 | Novel tetracyclic compound |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4/106482 | 1992-04-24 | ||
JP10648292 | 1992-04-24 | ||
JP4/342710 | 1992-12-22 | ||
JP34271092 | 1992-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993022286A1 true WO1993022286A1 (en) | 1993-11-11 |
Family
ID=26446598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1993/000527 WO1993022286A1 (en) | 1992-04-24 | 1993-04-23 | Novel tetracyclic compound |
Country Status (9)
Country | Link |
---|---|
US (1) | US5371225A (ja) |
EP (1) | EP0601191B1 (ja) |
JP (1) | JP2928385B2 (ja) |
AT (1) | ATE168679T1 (ja) |
CA (1) | CA2111955C (ja) |
DE (1) | DE69319859T2 (ja) |
DK (1) | DK0601191T3 (ja) |
ES (1) | ES2120498T3 (ja) |
WO (1) | WO1993022286A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5428040A (en) * | 1993-08-31 | 1995-06-27 | The Du Pont Merck Pharmaceutical Company | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents |
EP2583678A2 (en) | 2004-06-24 | 2013-04-24 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995009153A1 (fr) * | 1993-09-28 | 1995-04-06 | Kyowa Hakko Kogyo Co., Ltd. | Nouveau compose tetracyclique |
AU6123099A (en) * | 1998-10-15 | 2000-05-01 | Takeda Chemical Industries Ltd. | Process for the preparation of amine derivatives |
EP1237546A2 (en) * | 1999-10-01 | 2002-09-11 | Institute of Molecular and Cell Biology | Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
US6841561B1 (en) | 1999-10-01 | 2005-01-11 | Institute Of Molecular And Cell Biology | Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
DE10047118A1 (de) * | 2000-09-22 | 2002-04-11 | Bayer Ag | Verfahren zur Herstellung von Ketocarbonsäurederivaten |
AU2014352920A1 (en) | 2013-11-22 | 2016-06-23 | Genzyme Corporation | Novel methods for treating neurodegenerative diseases |
CN114031606B (zh) * | 2020-12-07 | 2023-01-24 | 广东聚华印刷显示技术有限公司 | 茚并喹啉类化合物及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4918077A (en) * | 1989-01-25 | 1990-04-17 | E. I. Du Pont De Nemours & Co., Inc. | 3-phenyl-5,6-dihydrobenz(c)acridine-7-carboxylic acids and related compounds as cancer chemotherapeutic agents |
WO1992000739A1 (en) * | 1990-07-06 | 1992-01-23 | The Du Pont Merck Pharmaceutical Company | 3-phenyl-5,6-dihydrobenz[c]acridine-7-carboxylic acids and related compounds as immunosuppresive agents |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5084462A (en) * | 1988-04-26 | 1992-01-28 | The Du Pont Merck Pharmaceutical Company | 4-quinoline carboxylic acid derivatives useful as immunosuppressive agents |
-
1993
- 1993-04-23 DK DK93909411T patent/DK0601191T3/da active
- 1993-04-23 CA CA002111955A patent/CA2111955C/en not_active Expired - Fee Related
- 1993-04-23 JP JP5519122A patent/JP2928385B2/ja not_active Expired - Fee Related
- 1993-04-23 ES ES93909411T patent/ES2120498T3/es not_active Expired - Lifetime
- 1993-04-23 DE DE69319859T patent/DE69319859T2/de not_active Expired - Fee Related
- 1993-04-23 AT AT93909411T patent/ATE168679T1/de not_active IP Right Cessation
- 1993-04-23 WO PCT/JP1993/000527 patent/WO1993022286A1/ja active IP Right Grant
- 1993-04-23 EP EP93909411A patent/EP0601191B1/en not_active Expired - Lifetime
- 1993-04-23 US US08/170,192 patent/US5371225A/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4918077A (en) * | 1989-01-25 | 1990-04-17 | E. I. Du Pont De Nemours & Co., Inc. | 3-phenyl-5,6-dihydrobenz(c)acridine-7-carboxylic acids and related compounds as cancer chemotherapeutic agents |
WO1992000739A1 (en) * | 1990-07-06 | 1992-01-23 | The Du Pont Merck Pharmaceutical Company | 3-phenyl-5,6-dihydrobenz[c]acridine-7-carboxylic acids and related compounds as immunosuppresive agents |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5428040A (en) * | 1993-08-31 | 1995-06-27 | The Du Pont Merck Pharmaceutical Company | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents |
US5639759A (en) * | 1993-08-31 | 1997-06-17 | The Dupont Merck Pharmaceutical Company | Carbocyclic and heterocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents |
US5874441A (en) * | 1993-08-31 | 1999-02-23 | Dupont Pharmaceuticals Company | Carbocyclic and hetertocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents |
US6110910A (en) * | 1993-08-31 | 2000-08-29 | Dupont Pharmaceuticals | Carbocyclic heterocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents |
EP2583678A2 (en) | 2004-06-24 | 2013-04-24 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
Also Published As
Publication number | Publication date |
---|---|
DK0601191T3 (da) | 1999-04-26 |
DE69319859T2 (de) | 1998-12-17 |
ATE168679T1 (de) | 1998-08-15 |
EP0601191A1 (en) | 1994-06-15 |
DE69319859D1 (de) | 1998-08-27 |
US5371225A (en) | 1994-12-06 |
CA2111955A1 (en) | 1993-11-11 |
JP2928385B2 (ja) | 1999-08-03 |
CA2111955C (en) | 2002-03-05 |
EP0601191B1 (en) | 1998-07-22 |
ES2120498T3 (es) | 1998-11-01 |
EP0601191A4 (en) | 1994-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3248902B2 (ja) | ハロゲン置換四環式テトラヒドロフラン誘導体 | |
JPH07503724A (ja) | 血中脂質低下性ベンゾチアゼピン化合物 | |
JPH04253978A (ja) | ピラゾロピリジン化合物およびその製造法 | |
US5614518A (en) | Morpholine derivatives as dopamine receptor subtype ligands | |
JP2012501346A5 (ja) | ||
EP0721942B1 (en) | Tetracyclic compound | |
OA11820A (en) | Functionalized heterocycles as chemokine receptor modulators. | |
EP3224261A1 (en) | Opioid receptor modulators | |
MX2007010063A (es) | Benzoxazol-carboxamidas para el tratamiento de la naucea y el vomito inducidos por quimioterapia y sindrome del intestino irritable con diarrea predominante. | |
JPH08502056A (ja) | 5−ht▲下4▼アンタゴニスト | |
EP3426244A1 (en) | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | |
TW201208687A (en) | Condensed ring pyridine compound | |
WO1993022286A1 (en) | Novel tetracyclic compound | |
JPH0568476B2 (ja) | ||
JPH08510221A (ja) | Ampa拮抗薬およびそれを用いての治療方法 | |
TW210338B (ja) | ||
WO1999033804A1 (fr) | Derives de tetrahydrobenzindole | |
TWI299733B (en) | SUBSTITUTED 2-PYRIDINYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE AND 7-PYRIDINYL-2,3-DIHYDROIMIDAZO[1,2-a] PYRIMIDIN-5(1H)ONE DERIVATIVES | |
TWI442922B (zh) | 乙胺化合物及其使用方法 | |
KR101082227B1 (ko) | 피라졸로피리미딘 화합물의 메탄술폰산염, 그 결정 및 그제조 방법 | |
JPH10505332A (ja) | アシルイミダゾピリジン | |
US4927819A (en) | Cyclo-octane neuroprotective agents | |
SE453293B (sv) | 3,3-dialkyl- och 3,3-alkylen-indolinderivat, sett att framstella dessa och farmaceutiska kompositioner innehallande desamma | |
EP0463691A2 (en) | Tricyclic sigma ligands | |
JP2956788B2 (ja) | スピロイソインドリン化合物、その製造方法、それを含有する神経症を治療するための医薬およびそれを製造するための中間体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2111955 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993909411 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08170192 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1993909411 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1993909411 Country of ref document: EP |